Oculatek^TM, Inc. is commercializing the Oculatek 9000 Trans-Scleral Light Therapy System, a novel therapeutic non-surgical ophthalmology devices which utilize low intensity light to improve vision. The product is a small, fully developed desktop device, with an extensive history of use. Over the last 10 years, approximately 500,000 patients have been successfully treated with Oculatek’s technology. Oculatek’s products treat vision disorders that afflict approximately half of the US population including:

• Presbyopia (age related inability to focus on close objects)
• Myopia (nearsightedness)
• Hyperopia (farsightedness)
• Post-surgical maintenance treatment
• Eye strain and fatigue

The Oculatek 9000 Trans-Scleral Light Therapy System directs low intensity light at the ciliary muscles which control accommodation (automatic visual adjustment of the eye for seeing at different distances). The wavelength of light has been optimized to stimulate these muscles by enhancing circulation and mitochondrial activity. Enhanced muscle tone improves accommodation, resolving mild cases of common vision disorders and avoiding the need for glasses, contact lenses or surgery. Depending on the selected protocol, the patient receives several weekly treatments, which provide improved vision for approximately 6 months. Treatment is repeated every 6 months for sustained benefits.

Oculatek^TM is ready to launch this exciting new therapy system to the $18 billion ophthalmology market.